ArticleBiotechnology journal2026
Pioneer Factor FOXA1 Boosts CHO Cell Productivity.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pioneer Factor FOXA1 Boosts CHO Cell Productivity.Biotechnology journal · 2026Article
- NOD1 modulates chronic obstructive pulmonary disease progression via FOXA1/NLRP3-mediated regulation of pyroptosis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Industrial production of biologics commonly involves the integration of transgenes into the genomes of host cells, such as Chinese hamster ovary (CHO) cells. A major determinant of productivity is the epigenetic control of the transgene promoter, accessibility of which can decrease during production due to the spread of heterochromatin. Pioneer factors such as forkhead box A1 (FOXA1) can bind heterochromatin, increase its accessibility and facilitate transcription of target genes. We show that FOXA1 can bind the EF1α and CMV promoters, which are widely used in industry. Overexpressing FOXA1 in CHO-K1 or an industrially-relevant CHO-DG44 cell line raised production of monoclonal antibody encoded by transgenes transcribed from these promoters. Mechanistically, this response can be attributed to recruitment by FOXA1 of epigenetic modifiers and a chromatin remodeling complex, which reprogram the promoter to optimize transcription. In parallel, FOXA1 overexpression induces endogenous genes with beneficial effects on cell viability. This strategy significantly enhanced cell-specific productivity, demonstrating potential benefit in biomanufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.